Brand vs Compounded Semaglutide: Is the Price Gap Worth It?
Brand Wegovy lists near $1,349/month; compounded semaglutide runs $145-299. The gap buys FDA approval, trial evidence, and manufacturing oversight — real value some patients need and others can forgo. Brand Wegovy lists near $1,349 but drops to about $349 self-pay or as low as $25 with covered insurance, while compounded runs $145-299 without FDA approval; the gap buys regulatory review and trial evidence.
- Brand Wegovy: ~$1,349 list, ~$349 NovoCare self-pay, as low as ~$25 insured copay.
- Compounded semaglutide: ~$145-299/month cash, but not FDA-approved.
- The gap buys FDA review, STEP/SELECT trial evidence, and manufacturing consistency.
- If insured, brand often wins on price too; uninsured, compounded is usually cheaper.
The price gap
Brand Wegovy lists near $1,349 per 28 days. Compounded semaglutide runs roughly $145 to $299 per month. On sticker price, compounded wins by a wide margin. But list price is rarely what a brand patient pays: NovoCare self-pay brings Wegovy to about $349 per month, and an insured copay with a savings card can fall to about $25.
So the real comparison depends entirely on your insurance. Priced correctly, the gap can be enormous or nearly closed.
What the gap buys
The price difference is not arbitrary. Brand semaglutide is FDA-approved, meaning it passed review for safety, effectiveness, and manufacturing quality. It carries the STEP and SELECT trial evidence directly. Every vial is manufactured to a consistent specification.
Compounded semaglutide has none of these. It is not FDA-approved, the FDA does not verify it before marketing, and it carries no formulation-specific trial evidence. That is the trade-off for the lower price — not necessarily a dealbreaker, but a real difference a patient should understand.
| Option | Monthly | FDA-approved? | Trial evidence |
|---|---|---|---|
| Insured Wegovy copay | ~$25 | Yes | Yes (STEP/SELECT) |
| Compounded semaglutide | $145–299 | No | No |
| Wegovy NovoCare self-pay | ~$349 | Yes | Yes |
| Wegovy list | ~$1,349 | Yes | Yes |
If you have insurance
For an insured patient whose plan covers Wegovy, brand often wins on both price and safety. A $25 copay undercuts every compounded option and delivers the approved product. The obstacle is coverage: many plans require prior authorization and a documented obesity diagnosis, and Medicare excludes weight-loss GLP-1s under current law.
Check your copay first. If it exists, the brand-versus-compounded question often answers itself in favor of brand.
| Feature | Brand | Compounded |
|---|---|---|
| FDA approval | Yes | No |
| Trial evidence | Yes | No |
| Manufacturing review | Yes | No |
| Lower cash price | No | Yes |
If you are paying cash
Uninsured, the math shifts. Compounded semaglutide at $145 to $299 is substantially cheaper than brand self-pay at $349, and for many cash-pay patients that difference determines whether treatment is affordable at all. The decision becomes whether the savings justify a non-FDA-approved product.
There is no universal answer. A patient who values the approval and trial backing may choose brand self-pay; one for whom cost is the binding constraint may reasonably choose compounded from a verified, licensed pharmacy. A prescriber should guide the choice.
Frequently asked questions
Is compounded semaglutide as good as Wegovy?
It contains semaglutide but is not FDA-approved and has no formulation-specific trial evidence. Whether it is 'as good' cannot be assumed; the approved product has the evidence behind it.
Why is brand so much more expensive?
Brand price reflects FDA approval, trial development, and manufacturing oversight. Compounded skips those, which is why it is cheaper and also why it lacks their guarantees.
Which should I choose?
If insured with coverage, brand often wins on price and safety. Uninsured, compounded is usually cheaper. A clinician should guide the decision.
Sources
- FDA — human drug compounding and GLP-1 status.
- NovoCare and manufacturer pricing, captured July 2026.
- Clinical trials via NEJM (STEP, SELECT, SURMOUNT, SURPASS).